Researchers reviewed how artificial intelligence (AI) is being used to manage triple-negative breast cancer. AI tools are currently being tested in several areas, including imaging like ultrasound and mammography, as well as digital pathology and genomics. These tools aim to help doctors identify tumor types, segment lesions, and predict how a patient might respond to specific treatments.
The review found that combining different types of data, such as medical images and genetic information, may be the most effective way to capture the complex nature of this cancer. This approach is called multimodal fusion. By looking at multiple layers of data at once, these systems may provide a more complete picture for doctors to use in planning care.
However, it is important to note that much of this research is still in early stages. Many studies involved small groups of patients and lacked extensive testing across different hospitals or machines. Because the evidence is currently limited by these factors, these tools are not yet standard practice. They are currently being explored as ways to support clinical decisions rather than replacing traditional methods.